Sensus Healthcare (NASDAQ:SRTS - Get Free Report) had its target price cut by equities research analysts at Lake Street Capital from $18.00 to $13.00 in a report released on Tuesday,Benzinga reports. The firm currently has a "buy" rating on the stock. Lake Street Capital's target price indicates a potential upside of 196.47% from the stock's current price.
Several other research analysts have also recently commented on SRTS. HC Wainwright upped their target price on shares of Sensus Healthcare from $11.00 to $12.00 and gave the stock a "buy" rating in a research report on Monday, February 10th. Maxim Group increased their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the stock a "buy" rating in a report on Friday, November 15th.
Check Out Our Latest Report on Sensus Healthcare
Shares of NASDAQ SRTS traded up $0.04 during mid-day trading on Tuesday, hitting $4.39. The company had a trading volume of 60,184 shares, compared to its average volume of 367,445. The stock has a market cap of $72.33 million, a price-to-earnings ratio of 10.94 and a beta of 1.28. The firm's 50 day simple moving average is $6.23 and its two-hundred day simple moving average is $6.71. Sensus Healthcare has a 12 month low of $2.91 and a 12 month high of $9.33.
Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. Equities analysts forecast that Sensus Healthcare will post 0.32 earnings per share for the current year.
A number of hedge funds have recently made changes to their positions in SRTS. Renaissance Technologies LLC increased its position in shares of Sensus Healthcare by 5.3% during the 4th quarter. Renaissance Technologies LLC now owns 430,934 shares of the company's stock valued at $2,982,000 after purchasing an additional 21,600 shares during the period. Dimensional Fund Advisors LP boosted its stake in Sensus Healthcare by 30.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company's stock valued at $2,620,000 after buying an additional 88,953 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in Sensus Healthcare by 81.2% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company's stock worth $1,039,000 after acquiring an additional 67,269 shares during the period. Geode Capital Management LLC raised its position in Sensus Healthcare by 8.5% in the third quarter. Geode Capital Management LLC now owns 146,404 shares of the company's stock worth $849,000 after acquiring an additional 11,525 shares in the last quarter. Finally, Marshall Wace LLP lifted its holdings in Sensus Healthcare by 99.6% in the 4th quarter. Marshall Wace LLP now owns 132,286 shares of the company's stock valued at $915,000 after acquiring an additional 65,994 shares during the last quarter. Institutional investors and hedge funds own 25.30% of the company's stock.
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Sensus Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sensus Healthcare wasn't on the list.
While Sensus Healthcare currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.